Drug intelligence / Profile preview

cytarabine + eltrombopag

Development stage
Preclinical
Lead developer
GSK
Modality
Small Molecules
Administration
Oral, Intravenous, Subcutaneous, Intrathecal
01

Overview

Cytarabine + eltrombopag is a combination of two pharmaceutical agents used primarily in hematological conditions. Cytarabine is an antimetabolite chemotherapy agent that inhibits DNA synthesis by acting as a cytosine nucleoside analog; it is mainly used to treat acute myeloid leukemia and other leukemias. Eltrombopag is a small molecule thrombopoietin receptor agonist that stimulates the production of platelets by binding to the transmembrane domain of the thrombopoietin receptor, activating the JAK/STAT signaling pathway and promoting megakaryocyte proliferation and differentiation[3][5][6]. Eltrombopag is indicated for chronic immune thrombocytopenia (ITP), severe aplastic anemia, and thrombocytopenia associated with hepatitis C[1][2][3][4]. The combination may be considered in clinical settings where both increased platelet production and anti-leukemic activity are desired.

Other names
Ara-C (for cytarabine)
02

Targets

DNA polymerase familyTPOR (Thrombopoietin receptor)

Beyond the preview

Go deeper on cytarabine + eltrombopag.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on cytarabine + eltrombopag.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call